Abstract
Background: The United States has recently experienced extensive changes in state policy regarding the use of cannabis for recreational and medicinal purposes. Despite its rapidly increasing accessibility and social acceptance, there is a striking dearth of research on cannabis as a treatment for medical and psychological conditions. Research on cannabis is difficult to conduct as it is classified as a schedule I drug with high potential for abuse and currently not accepted to be medically used in treatment. As a result, no standard dosing procedures exist and the lack of conclusive scientific evidence has left clinical providers without evidence-based guidelines about if, when, and how to guide clients on using cannabis safely.
Objective: To (1) provide critical psychoeducational information about cannabis and cannabis problems to guide client-provider conversations about cannabis use and (2) describe common clinical concerns around cannabis use, highlight special considerations for vulnerable populations, and review harm reduction techniques and practical resources that may help clinicians and their clients navigate safer cannabis use.
Conclusion: The removal of regulatory barriers would enable researchers to address key public health questions about the potential therapeutic and adverse effects of cannabis use. Additionally, funds for research, clinician education, and public health education initiatives are necessary to reduce risks associated with cannabis use in the United States.
Keywords: Cannabis, marijuana, mental health, harm reduction, substance use, psychoeducational information.
Graphical Abstract
[1]
National Conference of State Legislatures. State medical marijuana lawsWashington, DC: National Conference of State Legislatures 2018 Available from: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (Accessed on 31 Oct 2018).
[2]
United Nations Office on Drugs and Crime World drug report
2017. New York, NY: United Nations Publications; 2017. Available
from: . https://www.unodc.org/ wdr2017/en/press.html (Accessed
on 31 Oct 2018).
[3]
CBHSQ Receipt of services for behavioral health problems: results
from the 2014 National Survey on Drug Use and Health. Rockville,
MD: SAMHSA; 2017. Available from: . https://www. samhsa.gov/ data/sites/default/files/NSDUH-DR-FRR3-2014/NSDUH-DR-FRR3- 2014/NSDUH-DR-FRR3-2014.htm (Accessed on 31 Oct 2018).
[4]
Hasin DS, Sarvet AL, Cerdá M, et al. US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws. JAMA Psychiatry 2017; 74(6): 579-88.
[5]
Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ. Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry 2016; 73(3): 300-1.
[6]
Smith A. The U.S. legal marijuana industry is booming [Internet].
Atlanta, GA: CNN Money; 2018 Jan 31 (cited 2018 March 3).
Available from: http://money.cnn.com/2018/01/31/news/marijuana-state-of-the-union/index.html (Accessed on 31 Oct 2018).
[7]
Bonn-Miller MO, Harris AH, Trafton JA. Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv 2012; 9(4): 404-16.
[8]
Hughes A, Lipari RN, Williams MR. The CBHSQ Report: marijuana use and perceived risk of harm from marijuana use varies within and across statesSAMHSA; 2016 Available from https://www.samhsa.gov/data/sites/default/files/report_2404/ShortReport-2404.html (Accessed on 31 Oct 2018).
[9]
Okaneku J, Vearrier D, McKeever RG, LaSala GS, Greenberg MI. Change in perceived risk associated with marijuana use in the United States from 2002 to 2012. Clin Toxicol (Phila) 2015; 53(3): 151-5.
[10]
Ewing SWF, Lovejoy TI, Choo EK. How has legal recreational cannabis affected adolescents in your state? A window of opportunity. Am J Public Health 2017; 107(2): 246-7.
[11]
Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO. Training and practices of cannabis dispensary staff. Cannabis Cannabinoid Res 2016; 1(1): 244-51.
[12]
Choo EK, Ewing SW, Lovejoy TI. Opioids out, cannabis in: negotiating the unknowns in patient care for chronic pain. JAMA 2016; 316(17): 1763-4.
[13]
National Academies of Sciences. Engineering and Medicine Challenges and barriers in conducting cannabis research. Washington, DC: National Academies Press 2017; pp. 377-93.
[14]
Reardon S. Marijuana gears up for production high in US labs: researchers will score more-powerful varieties of the drug courtesy of the National Institute on Drug Abuse. Nature 2015; 519(7543): 269-71.
[15]
El-Sohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005; 78(5): 539-48.
[16]
Aizpurua-Olaizola O, Soydaner U, Öztürk E, et al. Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. J Nat Prod 2016; 79(2): 324-31.
[17]
Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot 2004; 91(6): 966-75.
[18]
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42(4): 327-60.
[19]
Morabito D, Soyster P, Ramey-Wright S, Belendiuk KA, Bonn-Miller MO. A review of recent advances in the therapeutic uses of secondary cannabinoids. Curr Addict Rep 2016; 3(2): 230-8.
[20]
Aizpurua-Olaizola O, Omar J, Navarro P, Olivares M, Etxebarria N, Usobiaga A. Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry. Anal Bioanal Chem 2014; 406(29): 7549-60.
[21]
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. Br J Pharmacol 2011; 163(7): 1344-64.
[22]
Zuardi AW, Hallak JE, Crippa JA. Interaction between cannabidiol (CBD) and ∆ 9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) 2012; 219(1): 247-9.
[23]
Cohen NL, Heinz AJ, Ilgen M, Bonn-Miller MO. Pain, cannabis species, and cannabis use disorders. J Stud Alcohol Drugs 2016; 77(3): 515-20.
[24]
Belendiuk KA, Babson KA, Vandrey R, Bonn-Miller MO. Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users. Addict Behav 2015; 50: 178-81.
[25]
Small E. Evolution and classification of Cannabis sativa (marijuana, hemp) in relation to human utilization. Bot Rev 2015; 81(3): 189-294.
[27]
Baggio S, Deline S, Studer J, Mohler-Kuo M, Daeppen JB, Gmel G. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. J Adolesc Health 2014; 54(2): 235-40.
[28]
Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006; 95(6): 1308-17.
[29]
Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav 2014; 39(10): 1430-3.
[30]
Corral VL. Differential effects of medical marijuana based on strain and route of administration: a three-year observational study. J Cannabis Therapeut 2001; 1(3-4): 43-59.
[31]
Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been. Headache 2015; 55(6): 885-916.
[32]
Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012; 13(5): 438-49.
[33]
Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis. Eur J Pain 2016; 20(6): 936-48.
[34]
Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care and STDS 2004; 18(4): 215-28.
[35]
O’Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 2007; 4(1 Available from:)https://harmreductionjournal.biomedcentral.com/articles/10.1186/1477-7517-4-16
[36]
Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs 2011; 43(2): 128-35.
[37]
Roy‐Byrne P, Maynard C, Bumgardner K, et al. Are medical marijuana users different from recreational users? The view from primary care. Am J Addict 2015; 24(7): 599-606.
[38]
Bonn-Miller MO, Zvolensky MJ, Bernstein A. Marijuana use motives: Concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers. Addict Behav 2007; 32(1): 49-62.
[39]
Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med 2014; 370(23): 2219-27.
[40]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington, VA: American Psychiatric Pub 2013.
[41]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: Author 2000.
[42]
Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend 2010; 110(1-2): 137-43.
[43]
Bonn-Miller MO, Heinz AJ, Smith EV, Bruno R, Adamson S. Preliminary Development of a Brief Cannabis Use Disorder Screening Tool: The Cannabis Use Disorder Identification Test Short-Form. Cannabis Cannabinoid Res 2016; 1(1): 252-61.
[44]
Manuel JK, Hagedorn HJ, Finney JW. Implementing evidence-based psychosocial treatment in specialty substance use disorder care. Psychol Addict Behav 2011; 25(2): 225-37.
[45]
Harrison LD, Martin SS, Enev T, Harrington D. Comparing drug testing and self-report of drug use among youths and young adults in the general populationRockville, MD: Substance Abuse and
Mental Health Services Administration, Office of Applied Studies
2007 May 214 p Report No: (SMA) 07-4249
[46]
Hjorthøj CR, Hjorthøj AR, Nordentoft M. Validity of timeline follow-back for self-reported use of cannabis and other illicit substances-systematic review and meta-analysis. Addict Behav 2012; 37(3): 225-33.
[47]
Thomas BF. Cannabidiol as a Treatment for Seizures, Convulsions and Epilepsy.In: Chandra S, Lata H, ElSohly M, editors.Cannabis sativa L-Botany and Biotechnology. New York: Springer International Publishing 2017; pp. 249-61.
[48]
Miller LL, Drew WG. Cannabis: Review of behavioral effects in animals. Psychol Bull 1974; 81(7): 401.
[49]
Baron EP. Medicinal properties of Cannabinoids, Terpenes, and Flavonoids in cannabis, and benefits in mirgraine, headache, and pain: an update on current evidence and cannabis science. Headache 2018; 58(7): 1139-86.
[50]
Rabinak CA, Angstadt M, Sripada CS, et al. Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 2013; 64: 396-402.
[51]
Loflin MJ, Babson KA, Bonn-Miller MO. Cannabinoids as therapeutic for PTSD. Curr Opin Psychol 2017; 14: 78-83.
[52]
Rabinak CA, Phan KL. Cannabinoid modulation of fear extinction brain circuits: a novel target to advance anxiety treatment. Curr Pharm Des 2014; 20(13): 2212-7.
[53]
Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011; 36(6): 1219.
[54]
Bonn-Miller MO, Boden MT, Vujanovic AA, Drescher KD. Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychol Trauma 2013; 5(2): 193-200.
[55]
Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry 2015; 76(9): 1174-80.
[56]
Fabre LF, McLendon DA. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981; 21(S1)
[57]
Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35(3): 764-74.
[58]
Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep 2017; 19(4): 23.
[59]
Bonn-Miller MO, Loflin MJ, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA 2017; 318(17): 1708-9.
[60]
Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA 2015; 313(24): 2491-3.
[61]
Crippa JA, Crippa A, Hallak JE, Martín-Santos R, Zuardi AWΔ. 9-THC intoxication by cannabidiol-enriched Cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol 2016; 7: 359.
[62]
Stone D. Cannabis, pesticides and conflicting laws: the dilemma for legalized States and implications for public health. Regul Toxicol Pharmacol 2014; 69(3): 284-8.
[63]
McKernan K, Spangler J, Helbert Y, et al. Metagenomic analysis of medicinal Cannabis samples; pathogenic bacteria, toxigenic fungi, and beneficial microbes grow in culture-based yeast and mold tests. F1000 Res 2016; 7: 2471.https://dx.doi. org/10.12688%2Ff1000research.9662.1 Available from:
[64]
McPartland JM, McKernan KJ. Contaminants of concern in Cannabis: microbes, heavy metals and pesticides.In: Chandra S, Lata H, ElSohly M, editors. Cannabis sativa L.-Botany and Biotechnology. New York: Springer International Publishing 2017; pp. 457- 74.
[65]
Hellerman C. Scientists say the government’s only pot farm has moldy samples – and no federal testing standardsArlington, VA: PBS NewsHour; 2017 Available from:. http://www.pbs.org/ newshour/updates/scientists-say-governments-pot-farm-moldy-samples- no-guidelines/ (Accessed on 31 Oct 2018).
[66]
Camchong J, Lim KO, Kumra S. Adverse effects of cannabis on adolescent brain development: A longitudinal study. Cereb Cortex 2017; 27(3): 1922-30.
[67]
Lichenstein SD, Musselman S, Shaw DS, Sitnick S, Forbes EE. Nucleus accumbens functional connectivity at age 20 is associated with trajectory of adolescent cannabis use and predicts psychosocial functioning in young adulthood. Addiction 2017; 112(11): 1961-70.
[68]
Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, Moffitt TE. Associations between adolescent cannabis use and
neuropsychological decline: A longitudinal cotwin control study. Addiction 2018; 113(2): 257-65.
[69]
Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: A systematic review. Pediatrics 2017; 140(5): e20171818.
[70]
Mark K, Terplan M. Cannabis and pregnancy: Maternal child health implications during a period of drug policy liberalization. Prev Med 2017; 104: 46-9.
[71]
Chabarria KC, Racusin DA, Antony KM, et al. Marijuana use and its effects in pregnancy. Am J Obstet Gynecol 2016; 215(4): 506.e1-7.
[72]
Grant KS, Petroff R, Isoherranen N, Stella N, Burbacher TM. Cannabis use during pregnancy: Pharmacokinetics and effects on child development. Pharmacol Ther 2017; 182: 133-51.
[73]
Worstell T, Gorman M, Caughey A. 233: Cannabis in pregnancy: Legal, but safe? Am J Obstet Gynecol 2015; 212(1): S129.
[74]
Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis. BMJ Open 2016; 6(4): e009986.
[75]
Wu CS, Jew CP, Lu HC. Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. Future Neurol 2011; 6(4): 459-80.
[76]
American College of Obstetricians and Gynecologists Committee Opinion 722: Marijuana use during pregnancy and lactation. Washington, D.C.: American College of Obstretricians and Gynecologists. 2017. Available from. https://www.acog.org/Clinical-Gui-dance-and-Publications/Committee-Opinions/Committee-on-Obs-tetric-Practice/Marijuana-Use-During-Pregnancy-and-Lactation (Accessed on 31 Oct 2018)
[77]
Volkow ND, Compton WM, Wargo EM. The risks of marijuana use during pregnancy. JAMA 2017; 317(2): 129-30.
[78]
Substance Abuse and Mental Health Services Administration Results from the 2012 National Survey on Drug Use and Health: summary of findings. Rockville, MD: SAMHSA; 2013, 164 p. Report No.: (SMA) 13-4795..
[79]
Blazer DG, Wu LT. The epidemiology of substance use and disorders among middle aged and elderly community adults: National survey on drug use and health. Am J Geriatr Psychiatry 2009; 17(3): 237-45.
[80]
DiNitto DM, Choi NG. Marijuana use among older adults in the USA: user characteristics, patterns of use, and implications for intervention. Int Psychogeriatr 2011; 23(5): 732-41.
[81]
Cigolle CT, Langa KM, Kabeto MU, Tian Z, Blaum CS. Geriatric conditions and disability: The Health and Retirement Study. Ann Intern Med 2007; 147(3): 156-64.
[83]
Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO. Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients. Addict Behav 2017; 72: 14-20.
[84]
Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioid-based pain medication: Patient self-report. Cannabis Cannabinoid Res 2017; 2(1): 160-6.
[85]
Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 2014; 174(10): 1668-73.
[86]
Piper BJ, DeKeuster RM, Beals ML, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol 2017; 31(5): 569-75.
[87]
Mané A, Bergé D, Penzol MJ, et al. Cannabis use, COMT, BDNF and age at first-episode psychosis. Psychiatry Res 2017; 250: 38-43.
[88]
Verweij KJ, Abdellaoui A, Nivard MG, et al. Genetic association between schizophrenia and cannabis use. Drug Alcohol Depend 2017; 171: 117-21.
[89]
Myles H, Myles N, Large M. Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust N Z J Psychiatry 2016; 50(3): 208-19.
[91]
Pedersen ER, Hummer JF, Rinker DV, Traylor ZK, Neighbors C. Measuring protective behavioral strategies for marijuana use among young adults. J Stud Alcohol Drugs 2016; 77(3): 441-50.
[92]
Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013; 69(5): 1135-47.
[93]
Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013; 33(2): 195-209.
[94]
Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S. Do plasma concentrations of Δ9‐tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 1981; 21(S1): 171S-7S.
Related Journals
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
Article Metrics
74
3